Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Martelli

Showing results (481-490 of 549) with videos related to

Pageof 55
Sort By:
Leukemia|March 14, 2008
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapyJ A McCubrey, L S Steelman, S L Abrams, et al.
Cells|May 6, 2020
Targeting GSK3 and Associated Signaling Pathways Involved in CancerPrzemysław Duda, Shaw M Akula, Stephen L Abrams, et al.
Oncotarget|July 7, 2011
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapyMelissa L Sokolosky, Kristin M Stadelman, William H Chappell, et al.
Oncotarget|December 17, 2013
MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemiaAnnalisa Astolfi, Francesca Vendemini, Milena Urbini, et al.
Advances in Biological Regulation|December 6, 2021
Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53Stephen L Abrams, Shaw M Akula, Linda S Steelman, et al.
Leukemia|April 5, 2014
Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysisJ Bertacchini, M Guida, B Accordi, et al.
Leukemia|March 14, 2008
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemiaL S Steelman, S L Abrams, J Whelan, et al.
Aging|April 27, 2022
Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic propertiesJames A McCubrey, Akshaya K Meher, Shaw M Akula, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patientsP L Zinzani, M Magagnoli, P Galieni, et al.
British Journal of Haematology|March 21, 2007
CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosisStefania Laurent, Giulio L Palmisano, Alberto M Martelli, et al.
Pageof 55

Showing results (481-490 of 549) with videos related to

Sort By:
Pageof 55
Leukemia|March 14, 2008
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapyJ A McCubrey, L S Steelman, S L Abrams, et al.
Cells|May 6, 2020
Targeting GSK3 and Associated Signaling Pathways Involved in CancerPrzemysław Duda, Shaw M Akula, Stephen L Abrams, et al.
Oncotarget|July 7, 2011
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapyMelissa L Sokolosky, Kristin M Stadelman, William H Chappell, et al.
Oncotarget|December 17, 2013
MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemiaAnnalisa Astolfi, Francesca Vendemini, Milena Urbini, et al.
Advances in Biological Regulation|December 6, 2021
Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53Stephen L Abrams, Shaw M Akula, Linda S Steelman, et al.
Leukemia|April 5, 2014
Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysisJ Bertacchini, M Guida, B Accordi, et al.
Leukemia|March 14, 2008
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemiaL S Steelman, S L Abrams, J Whelan, et al.
Aging|April 27, 2022
Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic propertiesJames A McCubrey, Akshaya K Meher, Shaw M Akula, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patientsP L Zinzani, M Magagnoli, P Galieni, et al.
British Journal of Haematology|March 21, 2007
CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosisStefania Laurent, Giulio L Palmisano, Alberto M Martelli, et al.
Pageof 55